NIH – Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01)
24/01/2019 08:17
Objetivo: Its objective is to stimulate research and technology development to promote the early-stage preclinical validation of therapeutic leads (that need not be finalized therapeutics, henceforth called “therapeutic leads”) such as small molecules or non-viral biologics (e.g. antibodies, cell-based therapies, engineered tissue constructs, probiotic or commensal microbes) that are not currently a focus within the biotechnology and pharmaceutical industries.
Inscrições: até 12 de fevereiro de 2019
Mais informações no site.
